USPTO serial 79333343
LINKINVAX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 30, 2023
- Examiner
- PETTICAN, NATHANIEL VINCIENT
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with LINKINVAX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
FR
FR
FR
FR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
James C. Watson
James C. Watson TraskBritt, P.C.230 South 500 East, #300Salt Lake City, UT 84102UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products for the treatment of infectious and parasitic diseases, diseases of viral or bacterial origin, dermatological diseases, metabolic diseases, endocrine diseases, eye diseases, ear, nose, and throat diseases, ear diseases, respiratory diseases, digestive system diseases, genito-urinary diseases, traumatic lesions, poisonings, cancers; vaccines; chemical preparations in the nature of medical preparations for medical use, namely, for the treatment of infectious and parasitic diseases, diseases of viral or bacterial origin, dermatological diseases, metabolic diseases, endocrine diseases, eye diseases, ear, nose, and throat diseases, ear diseases, respiratory diseases, digestive system diseases, genito-urinary diseases, traumatic lesions, poisonings, cancers; chemical preparations in the nature of pharmaceutical preparations for pharmaceutical use, namely, for the treatment of infectious and parasitic diseases, diseases of viral or bacterial origin, dermatological diseases, metabolic diseases, endocrine diseases, eye diseases, ear, nose, and throat diseases, ear diseases, respiratory diseases, digestive system diseases, genito-urinary diseases, traumatic lesions, poisonings, cancers | ACTIVE | — |
| 042 | Pharmaceutical research and development; pharmaceutical research and development in the nature of research, development, engineering and testing in the fields of pharmaceutical products, medicines and vaccines; pharmaceutical research and development in the nature of testing, inspection, research and development of pharmaceutical preparations, medicines and vaccines; pharmaceutical research and development in the nature of research and development services for vaccines and medicines; scientific research and development in the field of biotechnology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by 4A CONSULTING & ENGINEERING
- Other trademarks owned by 4A CONSULTING & ENGINEERING
- Other trademarks owned by 4A CONSULTING & ENGINEERING
- Other trademarks owned by LINKINVAX EUROPE
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named LINKINVAX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 27, 2024 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Sep 25, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 1, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 1, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 30, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 30, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 30, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 15, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 14, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 14, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 22, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 22, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 22, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 31, 2023 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Jan 13, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 12, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 12, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 12, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 2, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 13, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 13, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 23, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 22, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 21, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 19, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 15, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 10, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |